Exome Asset Management LLC Has $2.25 Million Stock Position in Glaukos Corporation $GKOS

Exome Asset Management LLC lessened its stake in shares of Glaukos Corporation (NYSE:GKOS) by 33.7% during the first quarter, Holdings Channel.com reports. The firm owned 20,874 shares of the medical instruments supplier’s stock after selling 10,597 shares during the period. Exome Asset Management LLC’s holdings in Glaukos were worth $2,247,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in GKOS. First Horizon Corp increased its position in Glaukos by 1,715.4% in the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 223 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Glaukos in the fourth quarter worth approximately $28,000. Larson Financial Group LLC boosted its holdings in Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 132 shares in the last quarter. Parallel Advisors LLC grew its stake in Glaukos by 159.2% in the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 226 shares during the period. Finally, Farther Finance Advisors LLC grew its stake in Glaukos by 111.4% in the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 215 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Leana Wen sold 1,700 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $143.35, for a total value of $243,695.00. Following the completion of the sale, the director owned 19,739 shares in the company, valued at $2,829,585.65. This represents a 7.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Alex R. Thurman sold 10,000 shares of the stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $140.00, for a total transaction of $1,400,000.00. Following the completion of the sale, the chief financial officer owned 43,681 shares of the company’s stock, valued at approximately $6,115,340. This represents a 18.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 61,273 shares of company stock valued at $8,882,003 in the last 90 days. Insiders own 5.90% of the company’s stock.

Glaukos Stock Down 1.0%

GKOS stock opened at $152.07 on Tuesday. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $161.53. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10. The stock’s 50 day moving average is $136.04 and its 200-day moving average is $123.80. The firm has a market capitalization of $8.93 billion, a PE ratio of -46.36 and a beta of 0.75.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The company had revenue of $150.57 million for the quarter, compared to analysts’ expectations of $137.00 million. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. Glaukos’s quarterly revenue was up 41.2% on a year-over-year basis. Sell-side analysts expect that Glaukos Corporation will post -0.57 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on GKOS. Stifel Nicolaus upped their target price on Glaukos from $170.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Piper Sandler reissued an “overweight” rating and issued a $165.00 price target on shares of Glaukos in a research report on Wednesday, July 1st. William Blair restated an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. Wells Fargo & Company upped their price objective on shares of Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $154.85.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.